Shots:

• GSK to get rights to develop and commercialize three additional inhaled therapies utilizing Liquidia’s PRINT technology and can acquire rights to pursue additional PRINT based inhalation therapies. Liquidia to receives milestones & royalties with the initiation of P-III studies
• In 2012- Liquidia & GSK collaborated to develop vaccines & inhaled therapies. Later in 2015- GSK exercised its option to license inhaled therapies developed utilizing PRINT technology except for LIQ861
• LIQ861 (treprostinil) is a dry powder formulation based on PRINT technology- being evaluated in P-III INSPIRE study for the treatment of pulmonary arterial hypertension with its expected NDA submission in 2019

Click here to read full press release/ article

Ref: Globe NewsWire | Image: GSK